EMEA-000128-PIP02-09-M02

Key facts

Invented name
Saxenda
Active substance
liraglutide
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0154/2016
PIP number
EMEA-000128-PIP02-09-M02
Pharmaceutical form(s)
Solution for injection (pre-filled pen)
Condition(s) / indication(s)
Treatment of obesity
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Novo Nordisk A/S
Denmark
Tel. +45 44448888
E-mail: paediatrics@novonordisk.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating